Principal Investigators




    Contact information of lead PI



    Title of project or programme

    Novel assays for assessing protein-protein interactions in Alzheimers disease

    Source of funding information

    NIH (NIA)

    Total sum awarded (Euro)


    Start date of award


    Total duration of award in years



    Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Bioengineering... Biotechnology... Brain Disorders... Dementia... Neurodegenerative... Neurosciences

    Research Abstract

    Abstract Cell-based assays more closely mimic biology than direct inhibition studies. Therefore, drug discovery companies are increasingly utilizing cellular screening assays. Current reporter systems are unable to reliably measure in-cell transient protein-protein interactions. Furthermore, many are based upon split enzyme systems, which require long incubation steps, are not real-time and are typically low throughput. In order to improve on these existing technologies, we will develop a split SUMOstar system engineered to contain a tetracysteine recognition motif for a biarsenical-based fluorophores. There are several advantages for using split a SUMOstar fluorescent reporter system, including relatively small fusions (~6 Kda) to the target proteins of interest, lower non-specific interaction with native proteins and the ability to take real-time measurements in high-throughput applications. Furthermore, using structural based mutagenesis, we can engineer the kinetics and binding affinity of the split SUMO interaction, allowing us to fine-tune the reporter assay to measure transient protein-protein interactions.

    Further information available at:

Types: Investments < €500k
Member States: United States of America
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF